Danielle Hinton

Danielle Hinton serves as a key procurement professional within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, supporting the agency’s mission to accelerate the acquisition of medical countermeasures for public health emergencies. She manages complex contracting actions focused on research and development of biodefense technologies, including vaccines, therapeutics, and diagnostic platforms. Her work directly enables rapid response capabilities against emerging infectious threats, bioterrorism, and pandemic risks through strategic sourcing of advanced biomedical solutions. Hinton maintains consistent procurement relationships with specialized biopharmaceutical and advanced drug delivery firms, including CIDARA THERAPEUTICS INC, AQUESTIVE THERAPEUTICS, INC., RAFA LABORATORIES LTD, and OSIVAX. These partnerships reflect a focus on innovative platforms such as antiviral therapeutics, novel vaccine delivery systems, and immunomodulatory technologies. Her contracting approach emphasizes technical rigor and scalability, prioritizing vendors with proven capabilities in GMP manufacturing, preclinical validation, and regulatory pathway alignment under BARDA’s unique acquisition authorities. Hinton’s portfolio is entirely non-set-aside, reflecting the urgent, mission-critical nature of the acquisitions she oversees. While small business participation is not formally prioritized through socioeconomic set-asides, her contracting strategy remains responsive to market capabilities, often engaging small innovators through other federal mechanisms such as SBIR/STTR programs or prime-subcontracting arrangements outside formal set-aside structures. Her procurement focus is concentrated in NAICS 541715 (Research and Development in Life Sciences) and 541714 (Biotechnology R&D), underscoring deep expertise in translational medical science. She routinely procures preclinical and clinical-stage countermeasures, including antiviral compounds, mRNA and viral vector platforms, and advanced pharmaceutical formulations, requiring specialized knowledge in regulatory compliance, biosafety, and emergency use authorization frameworks.